Best Drug Delivery Companies in United Kingdom
The 63 best Drug Delivery companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Oxular.
- Global Drug Delivery Market Up $6.3B in 2020 – Growth Driven by COVID-
- Rapid Drug Delivery Solution: Enhance Pharmacy’s Services With Mobile
Ranked: Best Drug Delivery companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Oxular Developer of drug delivery platform and therapeutics for ophthalmology | $58M | 63 mo ago | 6 | — | — | 79 patents Formulation and delivery systems for ocular therapeutics | — |
| 2 | Sisaf Provider of drug delivery nano silicon-based drug delivery systems | $33M | 66 mo ago | 18 18 → 17 (-6%) | Suzanne Siebert Founder & CEO | WordPressMySQLPHP+20 | 95 patents Silicon-based drug delivery platforms and therapeutic formulation technologies | — |
| 3 | ViaNautis Developer of targeted nanomedicines for drug delivery | $25M | 31 mo ago | — | Francesca Crawford Co-Founder & CEO | WordPressMySQLPHP+14 | — | — |
| 4 | Blueberry Therapeutics Developer of OTC and prescription products to treat infectious and inflammatory diseases | $24M | 60 mo ago | 15 | Michael Davies Co-Founder | — | 58 patents Antifungal topical pharmaceutical compositions and delivery methods for skin infections. | — |
| 5 | NanoSyrinx Developer of targeted intracellular delivery platform for biological molecules | $22M | 21 mo ago | 3 | Nick Waterfield Co-Founder | WordPressMySQLPHP+20 | — | — |
| 6 | Re-Vana Therapeutics Developer of drug delivery platform forophthalmic diseases | $17M | 42 mo ago | 1 | Michael O’Rourke CEO | — | 27 patents Biodegradable ocular drug‑delivery implants and compositions for eye therapeutics | — |
| 7 | Midatech Provider of novel drug delivery technologies for the treatment of diseases | $16M | 40 mo ago | 40 40 → 24 (-40%) | — | — | 204 patents Cyclodextrin and nanoparticle-based drug delivery systems for oncology and immunotherapy | 1 job opening · 1 expansion |
| 8 | Medherant Transdermal drug delivery patches | $13M | 38 mo ago | 18 18 → 16 (-11%) | David Haddleton Founder | WordPress Block EditorWordPressMySQL+17 | 43 patents Transdermal drug delivery patches and associated skin‑penetration formulations | — |
| 9 | Sixfold Bioscience Developer of oligonucleotide delivery systems | $10M | 54 mo ago | 16 | — | Webflowcore-jsjQuery+6 | 25 patents Nucleic‑acid nanoparticle platforms for therapeutic and diagnostic oligonucleotide delivery | — |
| 10 | OvalMedical Manufacturer of customizable autoinjector devices and contract development and manufacturing services | $8M | 135 mo ago | 25 | Ajay Singhvi Owner | — | — | — |
| 11 | Arecor Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery | $8M | 23 mo ago | 34 34 → 35 (+3%) | — | WordPressApple iCloud MailMicrosoft 365+21 | 288 patents Insulin delivery devices and pharmaceutical/biologic formulation technologies | — |
| 12 | Nebu~Flow Developer of aerosol delivery platform technology | $8M | 25 mo ago | 11 | Julien Reboud Co-Founder | — | — | — |
| 13 | NanoMedex Developing Nanotechnology of Microemulsions. | $8M | 177 mo ago | — | David Cooper President and CEO | — | — | — |
| 14 | Calla Lily Clinical Care Developer of a platform for improved vaginal drug delivery systems | $6M | 18 mo ago | 1 | Thang Vo-Ta Co-Founder & CEO | PHPVarnishPriority Hints+10 | — | 2 internships |
| 15 | Stable Pharma Developer of technology to store and deliver stable drugs and vaccines | $5M | 57 mo ago | 1 | — | WordPressMySQLPHP+24 | — | 1 launch · 3 partnerships |
| 16 | 1nhaler Developer of single‑dose, disposable, dry‑powder inhaler for conditions like asthma, epilepsy, allergies, and… | $5M | 7 mo ago | — | Don Smith Co-Founder | — | 39 patents Portable, foldable inhaler devices for delivering respiratory pharmaceuticals | — |
| 17 | StimOxyGen Developer of therapeutics for cancer treatment | $4M | 12 mo ago | — | Tony McHale Co-Founder | — | — | — |
| 18 | Somaserve Developer of cell imaging and bio nanoparticles | $3M | 64 mo ago | 5 | Francesca Crawford CEO | — | — | — |
| 19 | 1nhaler Developer of single dose and portable inhaler for drug delivery | $3M | 31 mo ago | 2 | Lisa McMyn Co-Founder & CEO | — | 39 patents Portable and foldable aerosol drug delivery inhaler devices | — |
| 20 | Nuformix Developer of drugs for the treatment of fibrosis and oncology | $2M | 38 mo ago | 4 | Stephen Cash Co-Founder | — | 48 patents Pharmaceutical cocrystal and salt forms of active drug molecules | — |
| 21 | LIFNano Therapeutics Nanoengineering platform to deliver Leukaemia Inhibitory Factor (LIF) | $2M | 144 mo ago | 2 | Su Metcalfe Founder | — | — | — |
| 22 | Atocap Manufacturer of microencapsulated drugs | $1M | 3 mo ago | 5 | Heather King CEO | — | — | — |
| 23 | Micropore CDMO focused on providing drug formulations manufacturing services | $1M | 77 mo ago | 13 | — | SanityFirebaseEmotion+16 | 9 patents Microporous membrane-based microfluidic devices for high‑shear phase dispersion and emulsification | — |
| 24 | SporeGen Provides vaccine delivery agents, probiotic foods, contract probiotic research services and reagents… | $1M | 137 mo ago | 6 | Simon Cutting CEO | — | 20 patents Engineered bacterial spores for targeted antimicrobial and antiviral drug delivery. | — |
| 25 | Ocelus Develops and commercializes a needle-free microimplant drug delivery system | $1M | 197 mo ago | — | Andrew Kirby Founder & ex-CEO | — | 8 patents Transdermal drug delivery via microneedle and needle‑free injection devices | — |
| 26 | Active Needle Developer of medical devices for ultrasound-guided interventional procedures | $1M | 55 mo ago | 2 | Ian Quirk CEO and Founder | — | 36 patents Provides advanced tattoo and medical injection devices with precision needle cartridges. | — |
| 27 | Alchemy Pharmatech Develops drug delivery platforms with focus in non-invasive intranasal delivery | $861K | 133 mo ago | 2 | Robert Clayborough CEO | — | 6 patents Advanced drug delivery devices such as syringes and inhalers for precise medicament administration | — |
| 28 | GreenTech Investment Holdings Developer of cannabis-derived drug delivery platform | $531K | 42 mo ago | — | Ian Grant Founder & President | — | — | — |
| 29 | VisusNano Developer of drug-eluting intraocular lens implants | $377K | 49 mo ago | 4 | — | — | 11 patents Drug‑eluting intraocular lens coatings and microsphere drug‑release systems for ocular therapy | — |
| 30 | C-Major Medical Developer of injury-free syringes and blood-collection systems | $275K | 67 mo ago | 6 | — | WordPressMySQLPHP+20 | — | — |
Top 12 Drug Delivery companies in United Kingdom
#1
Seed · Edinburgh, Scotland · founded 2017$4.7Mraised▾
Developer of single‑dose, disposable, dry‑powder inhaler for conditions like asthma, epilepsy, allergies, and Parkinsons. It offers a portable inhaler made from cardboard and it folds from a flat, credit‑card shape into a 3D inhaler activated by a single breath. The lead project is salbutamol for asthma relief.
- Nov 2025Seed$2M
- Nov 2023Seed$2.5M
- Mar 2022Seed$99.2K
- Apr 2019Seed$130.8K
#2
Seed · London, England · founded 2011 · 5 employees$1.3Mraised▾
Developer of a microencapsulation technology designed to deliver generic antibiotics for urinary tract infection with chemotherapeutics into a multi-layered capsule. The company's technology fabricates encapsulated products for controlled drug delivery for immunocompromised patients, pregnant women, and multiple sclerosis patients who are at a high risk of contracting UTI, enabling healthcare organizations to prepare a wide range of encapsulated structured drugs via a clean, efficient, one-step route.
- Feb 2026Seed$323.2K
- Nov 2020Seed$993.3K
- Oct 2020Seed$586.5K
- Feb 2017Seed$378.1K
#3
Seed · Londonderry, Northern Ireland · founded 2021$4Mraised▾
Developer of therapeutics for cancer treatment. It offers oxygen-generating nanoparticles that dissolve in acidic tumor environments to release oxygen and countering tumor hypoxia and improving the efficacy of radiotherapy and immunotherapy. It offers a lead candidate SGEN-33 designed to enhance radiotherapy outcomes by alleviating hypoxic resistance.
- Jun 2025Seed$2M
- Mar 2025Grant (prize money)—
- Mar 2025Seed$1.9M
#4
Series A · Coventry, England · founded 2018 · 3 employees$21.6Mraised▾
Developer of targeted intracellular delivery platform for biological molecules. The company focuses on enabling targeted, intracellular delivery of protein therapeutics. It creates a novel solution to the intracellular bioavailability problem. The company’s platform aims to unlock therapeutic opportunities within cells that are currently difficult to drug.
- Sep 2024Series A$13.1M
- Jul 2021Seed$8.5M
- Sep 2020Grant (prize money)—
- Sep 2020Seed—
#5
Seed · London, England · founded 2021 · 1 employees$5.7Mraised▾
Developer of a platform for improved vaginal drug delivery systems. The platform aims to address the limitations of current vaginal drug delivery methods. It focuses on improving dosage confidence and user convenience. The technology is under development and has not yet been approved for sale. The content provides general information about these products, their field of application and intended use. Their function, performance and specification are subject to further development and may deviate from those shown.
- Dec 2024Seed$3M
- Dec 2023Seed$1.6M
- Dec 2022Seed$492.3K
- Oct 2022Seed$574.6K
#6
Public · Cambridge, England · founded 2007 · 34 employees$8Mraised▾
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery. It has developed Arestat, a smart stabilization technology, which enables the formulation of labile proteins and vaccines as stable aqueous or dry preparations even at high concentrations or in the presence of ionizing radiation. As a simple reformulation, the technology can be integrated into existing manufacturing processes. Arestat does not involve the covalent modification of biologics and uses only GRAS (Generally Regarded As Safe) excipients approved by relevant regulatory authorities.
- Jul 2024Post IPO$8.3M
- Mar 2021Grant (prize money)$3.8M
- Sep 2018Series A$7.7M
- Jun 2018Grant (prize money)$1.3M
#7
Series A · Cambridge, England · founded 2018$25Mraised▾
Developer of targeted nanomedicines for drug delivery. The company utilizes proprietary technology "polyNaut" that can be formulated to encapsulate a wide array of genetic cargoes for viral and non-viral delivery for CNS diseases and cystic fibrosis.
- Nov 2023Series A$25M
#8
Series A · Glasgow, Scotland · founded 2019 · 11 employees$8Mraised▾
Developer of aerosol delivery platform technology
- Apr 2024Series A$5.9M
- Aug 2022Grant (prize money)$1.2M
- May 2022Seed$2.1M
#9
Public · Abingdon, England · founded 2000 · 40 employees$16Mraised▾
Provider of novel drug delivery technologies for the treatment of diseases. It develops a pipeline of product candidates in clinical and pre-clinical development for diseases such as diabetes, rare cancers including brain, ovarian, liver, and pancreatic cancer, and neurological/ophthalmologic conditions. It provides in-house technology platforms for sustained release to prolong and control the release of therapeutics over an extended period of time and dissolve insoluble drugs which can be converted into liquid form and can be treated for tumor patients.
- Feb 2023Post IPO$6M
- Aug 2020Post IPO$1M
- 2020Grant (prize money)$56.1K
- Oct 2019Post IPO$3M
#10
Series A · Coventry, England · founded 2015 · 18 employees$13.5Mraised▾
Medherant, a spin-out from the University of Warwick, manufactures transdermal drug delivery patches. They have manufactured, TEPI Patch, a higher-dosage drug delivery patch with a constant rate of drug release. Under their TEPI Patch technology, they offer Ibuprofen Patch and Methyl Salicylate Patch
- Apr 2023Series A$3.7M
- May 2019Series A$2.5M
- Dec 2017Series A$4.5M
- Sep 2016Seed$1.9M
#11
Acquired · Oxford, England · founded 2014 · 6 employees$57.5Mraised▾
Developer of drug delivery platform and therapeutics for ophthalmology. The leading programs, OXU-001 and OXU-003 enable the targeted delivery of drugs to posterior ocular tissues. The Oxusphere is a drug-containing biodegradable polymer system and Oxulumis is a semi-automated ocular administration device. The company is exploring indications in ophthalmic diseases, such as age-related macular degeneration, diabetic macular edema, and a few rare ophthalmic disorders.
- Mar 2021Series B$37M
- Jul 2016Series A$20.5M
#12
Series A · Belfast, Northern Ireland · founded 2015 · 1 employees$16.8Mraised▾
Developer of drug delivery platform for ophthalmic diseases. The company platform is meant for chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma. It offers a flagship product EyeLief, is a photo cross-linked sustained-release biodegradable implant delivering both biologic and small molecule drugs .
- Nov 2022Series A$11.9M
- 2020Seed$2.1M
- Jun 2020Seed$1.2M
- 2017Seed$1.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Drug Delivery coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Drug Discovery is moving in the United Kingdom
A read on the academic research around Drug Discovery — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,687 United Kingdom-affiliated papers.
- University of Cambridge196
- University of Oxford176
- Imperial College London171
- AstraZeneca131
- University College London107
- Computational biology35→175
- Chemical space6→79
- Small molecule14→82
- High-throughput screening1→69
- Virtual screening4→67
- Computational biology43→197
- Pharmacology11→85
- In silico4→77
- Virtual screening10→66
- Docking (animal)8→63
- Drug development14→57
- Disease3→34
- Bioinformatics5→31
- Computational biology44→67
- Data science8→31
Where drug discovery is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing drug discovery patents in the United Kingdom
United Kingdom drug discovery patent filing is cooling — 70,971 filings from 8,000 assignees (2016–2025), led by Unilever, Glaxo Group, Glaxosmithkline IP DEV; annual filings 6378→5999.
- Unilever8136
- Glaxo Group7572
- Glaxosmithkline IP DEV3417
- Medimmune3098
- UCL Business2121
- Syngenta2073
- Astex Therapeutics1799
- Unilever Global IP1748
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.